By Nick Johnson (Apyx) In 2023 Shareholder News, RenuvionPosted February 27, 2023APYX MEDICAL CORPORATION RECEIVES FDA 510(K) CLEARANCE FOR THE USE OF RENUVION TO COAGULATE AND CONTRACT SOFT TISSUES, INCLUDING SUBCUTANEOUS TISSUE, WHERE NEEDED READ MORE
By Nick Johnson (Apyx) In 2023 Shareholder News, J-Plasma, RenuvionPosted February 21, 2023APYX MEDICAL CORPORATION ANNOUNCES NEW FIVE-YEAR CREDIT AGREEMENT WITH MIDCAP FINANCIAL READ MORE
By apyxmedical In 2023 Shareholder News, J-Plasma, RenuvionPosted February 16, 2023APYX MEDICAL CORPORATION TO RELEASE FOURTH QUARTER AND FISCAL YEAR 2022 FINANCIAL RESULTS ON MARCH 16, 2023 READ MORE
By Nick Johnson (Apyx) In 2023 Shareholder News, RenuvionPosted February 9, 2023RENUVION COSMETIC NECK LAXITY PROCEDURE TO BE FEATURED ON ‘THE BALANCING ACT’ TALK SHOW ON LIFETIME FEBRUARY 13 READ MORE
By Nick Johnson (Apyx) In 2023 Shareholder News, RenuvionPosted February 1, 2023APYX MEDICAL CORPORATION ANNOUNCES FDA 510(K) SUBMISSION FOR THE USE OF THE RENUVION APR HANDPIECE FOR THE COAGULATION OF SUBCUTANEOUS SOFT TISSUES WHERE NEEDED, FOLLOWING LIPOSUCTION READ MORE
